Loading…
A chemically defined production process for highly attenuated poxviruses
Highly attenuated poxviruses are promising vectors for protective and therapeutic vaccines. These vectors do not replicate in human cells and can therefore be safely given even to immunocompromised recipients. They can accomodate very large inserts and provide strong stimulation of the immune system...
Saved in:
| Published in: | Biologicals 2011, Vol.39 (1), p.50-58 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c432t-cb9d292fa783c7296e8d7b27dd70909e3ce5b393317e66d41ca43c5a53d2a9833 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c432t-cb9d292fa783c7296e8d7b27dd70909e3ce5b393317e66d41ca43c5a53d2a9833 |
| container_end_page | 58 |
| container_issue | 1 |
| container_start_page | 50 |
| container_title | Biologicals |
| container_volume | 39 |
| creator | Jordan, Ingo Northoff, Stefan Thiele, Michael Hartmann, Stefan Horn, Deborah Höwing, Kristin Bernhardt, Holger Oehmke, Stefanie von Horsten, Henning Rebeski, Dierk Hinrichsen, Lars Zelnik, Vladimir Mueller, Wiebke Sandig, Volker |
| description | Highly attenuated poxviruses are promising vectors for protective and therapeutic vaccines. These vectors do not replicate in human cells and can therefore be safely given even to immunocompromised recipients. They can accomodate very large inserts and provide strong stimulation of the immune system against the vectored antigen. Disadvantages include that very high numbers of infectious units are required per dose for full efficacy. Because they are difficult to produce, improved cellular substrates and processes are urgently needed to facilitate programs intended to reach a large number of vaccinees. We have developed a fully scalable and very efficient chemically-defined production process for modified vaccinia Ankara (MVA), canarypox (CNPV, strain ALVAC) and fowlpox viruses (FPV) based on a continuous cell line. |
| doi_str_mv | 10.1016/j.biologicals.2010.11.005 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_902350568</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S104510561000182X</els_id><sourcerecordid>850559948</sourcerecordid><originalsourceid>FETCH-LOGICAL-c432t-cb9d292fa783c7296e8d7b27dd70909e3ce5b393317e66d41ca43c5a53d2a9833</originalsourceid><addsrcrecordid>eNqNkctOxCAUhonReH8FrStXHbmUUpZm4i0xcaGuCYXTGSadotAafXsho8adrjgh3znn5wOhM4JnBJP6YjVrne_9whndxxnF-Z7MMOZbaJ9gycuGUbyd64qXBPN6Dx3EuMKYkEpUu2iPEspELeg-ur0szBLWeVL_UVjo3AC2eAneTmZ0fsilgRiLzodi6RbLROlxhGHSYwb9-5sLU4R4hHa6lAaOv85D9Hx99TS_Le8fbu7ml_elqRgdS9NKSyXttGiYEVTW0FjRUmGtwBJLYAZ4yyRjREBd24oYXTHDNWeWatkwdojON3NTsNcJ4qjWLhroez2An6KSmDKentz8STYJ41JWmZQb0gQfY4BOvQS31uFDEayycbVSv4yrbFwRopLx1HvytWVq12B_Or8VJ-B0A3TaK70ILqrnxzSBp--oOSZ5_XxDQPL25iCoaBwMBqwLYEZlvftHkE8BoqFA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>850559948</pqid></control><display><type>article</type><title>A chemically defined production process for highly attenuated poxviruses</title><source>ScienceDirect Journals</source><creator>Jordan, Ingo ; Northoff, Stefan ; Thiele, Michael ; Hartmann, Stefan ; Horn, Deborah ; Höwing, Kristin ; Bernhardt, Holger ; Oehmke, Stefanie ; von Horsten, Henning ; Rebeski, Dierk ; Hinrichsen, Lars ; Zelnik, Vladimir ; Mueller, Wiebke ; Sandig, Volker</creator><creatorcontrib>Jordan, Ingo ; Northoff, Stefan ; Thiele, Michael ; Hartmann, Stefan ; Horn, Deborah ; Höwing, Kristin ; Bernhardt, Holger ; Oehmke, Stefanie ; von Horsten, Henning ; Rebeski, Dierk ; Hinrichsen, Lars ; Zelnik, Vladimir ; Mueller, Wiebke ; Sandig, Volker</creatorcontrib><description>Highly attenuated poxviruses are promising vectors for protective and therapeutic vaccines. These vectors do not replicate in human cells and can therefore be safely given even to immunocompromised recipients. They can accomodate very large inserts and provide strong stimulation of the immune system against the vectored antigen. Disadvantages include that very high numbers of infectious units are required per dose for full efficacy. Because they are difficult to produce, improved cellular substrates and processes are urgently needed to facilitate programs intended to reach a large number of vaccinees. We have developed a fully scalable and very efficient chemically-defined production process for modified vaccinia Ankara (MVA), canarypox (CNPV, strain ALVAC) and fowlpox viruses (FPV) based on a continuous cell line.</description><identifier>ISSN: 1045-1056</identifier><identifier>EISSN: 1095-8320</identifier><identifier>DOI: 10.1016/j.biologicals.2010.11.005</identifier><identifier>PMID: 21237672</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>AGE1.CR ; ALVAC ; Animals ; antigens ; Bioreactors ; Canarypox virus - genetics ; Canarypox virus - immunology ; Cell Line ; Cell Proliferation ; CHO Cells ; CR.pIX ; Cricetinae ; Cricetulus ; fowl pox ; Fowlpox ; Fowlpox virus - genetics ; Fowlpox virus - immunology ; Genetic Vectors - genetics ; Genetic Vectors - immunology ; Humans ; immune system ; MVA ; Poxviridae ; Poxviridae - genetics ; Poxviridae - immunology ; Vaccine production ; vaccines ; Vaccines, Attenuated - immunology ; Vaccinia virus - genetics ; Vaccinia virus - immunology ; Viral Vaccines - immunology ; Virus Replication - genetics ; viruses</subject><ispartof>Biologicals, 2011, Vol.39 (1), p.50-58</ispartof><rights>2010 The International Association for Biologicals</rights><rights>Copyright © 2010 The International Association for Biologicals. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c432t-cb9d292fa783c7296e8d7b27dd70909e3ce5b393317e66d41ca43c5a53d2a9833</citedby><cites>FETCH-LOGICAL-c432t-cb9d292fa783c7296e8d7b27dd70909e3ce5b393317e66d41ca43c5a53d2a9833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21237672$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jordan, Ingo</creatorcontrib><creatorcontrib>Northoff, Stefan</creatorcontrib><creatorcontrib>Thiele, Michael</creatorcontrib><creatorcontrib>Hartmann, Stefan</creatorcontrib><creatorcontrib>Horn, Deborah</creatorcontrib><creatorcontrib>Höwing, Kristin</creatorcontrib><creatorcontrib>Bernhardt, Holger</creatorcontrib><creatorcontrib>Oehmke, Stefanie</creatorcontrib><creatorcontrib>von Horsten, Henning</creatorcontrib><creatorcontrib>Rebeski, Dierk</creatorcontrib><creatorcontrib>Hinrichsen, Lars</creatorcontrib><creatorcontrib>Zelnik, Vladimir</creatorcontrib><creatorcontrib>Mueller, Wiebke</creatorcontrib><creatorcontrib>Sandig, Volker</creatorcontrib><title>A chemically defined production process for highly attenuated poxviruses</title><title>Biologicals</title><addtitle>Biologicals</addtitle><description>Highly attenuated poxviruses are promising vectors for protective and therapeutic vaccines. These vectors do not replicate in human cells and can therefore be safely given even to immunocompromised recipients. They can accomodate very large inserts and provide strong stimulation of the immune system against the vectored antigen. Disadvantages include that very high numbers of infectious units are required per dose for full efficacy. Because they are difficult to produce, improved cellular substrates and processes are urgently needed to facilitate programs intended to reach a large number of vaccinees. We have developed a fully scalable and very efficient chemically-defined production process for modified vaccinia Ankara (MVA), canarypox (CNPV, strain ALVAC) and fowlpox viruses (FPV) based on a continuous cell line.</description><subject>AGE1.CR</subject><subject>ALVAC</subject><subject>Animals</subject><subject>antigens</subject><subject>Bioreactors</subject><subject>Canarypox virus - genetics</subject><subject>Canarypox virus - immunology</subject><subject>Cell Line</subject><subject>Cell Proliferation</subject><subject>CHO Cells</subject><subject>CR.pIX</subject><subject>Cricetinae</subject><subject>Cricetulus</subject><subject>fowl pox</subject><subject>Fowlpox</subject><subject>Fowlpox virus - genetics</subject><subject>Fowlpox virus - immunology</subject><subject>Genetic Vectors - genetics</subject><subject>Genetic Vectors - immunology</subject><subject>Humans</subject><subject>immune system</subject><subject>MVA</subject><subject>Poxviridae</subject><subject>Poxviridae - genetics</subject><subject>Poxviridae - immunology</subject><subject>Vaccine production</subject><subject>vaccines</subject><subject>Vaccines, Attenuated - immunology</subject><subject>Vaccinia virus - genetics</subject><subject>Vaccinia virus - immunology</subject><subject>Viral Vaccines - immunology</subject><subject>Virus Replication - genetics</subject><subject>viruses</subject><issn>1045-1056</issn><issn>1095-8320</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqNkctOxCAUhonReH8FrStXHbmUUpZm4i0xcaGuCYXTGSadotAafXsho8adrjgh3znn5wOhM4JnBJP6YjVrne_9whndxxnF-Z7MMOZbaJ9gycuGUbyd64qXBPN6Dx3EuMKYkEpUu2iPEspELeg-ur0szBLWeVL_UVjo3AC2eAneTmZ0fsilgRiLzodi6RbLROlxhGHSYwb9-5sLU4R4hHa6lAaOv85D9Hx99TS_Le8fbu7ml_elqRgdS9NKSyXttGiYEVTW0FjRUmGtwBJLYAZ4yyRjREBd24oYXTHDNWeWatkwdojON3NTsNcJ4qjWLhroez2An6KSmDKentz8STYJ41JWmZQb0gQfY4BOvQS31uFDEayycbVSv4yrbFwRopLx1HvytWVq12B_Or8VJ-B0A3TaK70ILqrnxzSBp--oOSZ5_XxDQPL25iCoaBwMBqwLYEZlvftHkE8BoqFA</recordid><startdate>2011</startdate><enddate>2011</enddate><creator>Jordan, Ingo</creator><creator>Northoff, Stefan</creator><creator>Thiele, Michael</creator><creator>Hartmann, Stefan</creator><creator>Horn, Deborah</creator><creator>Höwing, Kristin</creator><creator>Bernhardt, Holger</creator><creator>Oehmke, Stefanie</creator><creator>von Horsten, Henning</creator><creator>Rebeski, Dierk</creator><creator>Hinrichsen, Lars</creator><creator>Zelnik, Vladimir</creator><creator>Mueller, Wiebke</creator><creator>Sandig, Volker</creator><general>Elsevier Ltd</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>2011</creationdate><title>A chemically defined production process for highly attenuated poxviruses</title><author>Jordan, Ingo ; Northoff, Stefan ; Thiele, Michael ; Hartmann, Stefan ; Horn, Deborah ; Höwing, Kristin ; Bernhardt, Holger ; Oehmke, Stefanie ; von Horsten, Henning ; Rebeski, Dierk ; Hinrichsen, Lars ; Zelnik, Vladimir ; Mueller, Wiebke ; Sandig, Volker</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c432t-cb9d292fa783c7296e8d7b27dd70909e3ce5b393317e66d41ca43c5a53d2a9833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>AGE1.CR</topic><topic>ALVAC</topic><topic>Animals</topic><topic>antigens</topic><topic>Bioreactors</topic><topic>Canarypox virus - genetics</topic><topic>Canarypox virus - immunology</topic><topic>Cell Line</topic><topic>Cell Proliferation</topic><topic>CHO Cells</topic><topic>CR.pIX</topic><topic>Cricetinae</topic><topic>Cricetulus</topic><topic>fowl pox</topic><topic>Fowlpox</topic><topic>Fowlpox virus - genetics</topic><topic>Fowlpox virus - immunology</topic><topic>Genetic Vectors - genetics</topic><topic>Genetic Vectors - immunology</topic><topic>Humans</topic><topic>immune system</topic><topic>MVA</topic><topic>Poxviridae</topic><topic>Poxviridae - genetics</topic><topic>Poxviridae - immunology</topic><topic>Vaccine production</topic><topic>vaccines</topic><topic>Vaccines, Attenuated - immunology</topic><topic>Vaccinia virus - genetics</topic><topic>Vaccinia virus - immunology</topic><topic>Viral Vaccines - immunology</topic><topic>Virus Replication - genetics</topic><topic>viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jordan, Ingo</creatorcontrib><creatorcontrib>Northoff, Stefan</creatorcontrib><creatorcontrib>Thiele, Michael</creatorcontrib><creatorcontrib>Hartmann, Stefan</creatorcontrib><creatorcontrib>Horn, Deborah</creatorcontrib><creatorcontrib>Höwing, Kristin</creatorcontrib><creatorcontrib>Bernhardt, Holger</creatorcontrib><creatorcontrib>Oehmke, Stefanie</creatorcontrib><creatorcontrib>von Horsten, Henning</creatorcontrib><creatorcontrib>Rebeski, Dierk</creatorcontrib><creatorcontrib>Hinrichsen, Lars</creatorcontrib><creatorcontrib>Zelnik, Vladimir</creatorcontrib><creatorcontrib>Mueller, Wiebke</creatorcontrib><creatorcontrib>Sandig, Volker</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Biologicals</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jordan, Ingo</au><au>Northoff, Stefan</au><au>Thiele, Michael</au><au>Hartmann, Stefan</au><au>Horn, Deborah</au><au>Höwing, Kristin</au><au>Bernhardt, Holger</au><au>Oehmke, Stefanie</au><au>von Horsten, Henning</au><au>Rebeski, Dierk</au><au>Hinrichsen, Lars</au><au>Zelnik, Vladimir</au><au>Mueller, Wiebke</au><au>Sandig, Volker</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A chemically defined production process for highly attenuated poxviruses</atitle><jtitle>Biologicals</jtitle><addtitle>Biologicals</addtitle><date>2011</date><risdate>2011</risdate><volume>39</volume><issue>1</issue><spage>50</spage><epage>58</epage><pages>50-58</pages><issn>1045-1056</issn><eissn>1095-8320</eissn><abstract>Highly attenuated poxviruses are promising vectors for protective and therapeutic vaccines. These vectors do not replicate in human cells and can therefore be safely given even to immunocompromised recipients. They can accomodate very large inserts and provide strong stimulation of the immune system against the vectored antigen. Disadvantages include that very high numbers of infectious units are required per dose for full efficacy. Because they are difficult to produce, improved cellular substrates and processes are urgently needed to facilitate programs intended to reach a large number of vaccinees. We have developed a fully scalable and very efficient chemically-defined production process for modified vaccinia Ankara (MVA), canarypox (CNPV, strain ALVAC) and fowlpox viruses (FPV) based on a continuous cell line.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>21237672</pmid><doi>10.1016/j.biologicals.2010.11.005</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1045-1056 |
| ispartof | Biologicals, 2011, Vol.39 (1), p.50-58 |
| issn | 1045-1056 1095-8320 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_902350568 |
| source | ScienceDirect Journals |
| subjects | AGE1.CR ALVAC Animals antigens Bioreactors Canarypox virus - genetics Canarypox virus - immunology Cell Line Cell Proliferation CHO Cells CR.pIX Cricetinae Cricetulus fowl pox Fowlpox Fowlpox virus - genetics Fowlpox virus - immunology Genetic Vectors - genetics Genetic Vectors - immunology Humans immune system MVA Poxviridae Poxviridae - genetics Poxviridae - immunology Vaccine production vaccines Vaccines, Attenuated - immunology Vaccinia virus - genetics Vaccinia virus - immunology Viral Vaccines - immunology Virus Replication - genetics viruses |
| title | A chemically defined production process for highly attenuated poxviruses |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T14%3A22%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20chemically%20defined%20production%20process%20for%20highly%20attenuated%20poxviruses&rft.jtitle=Biologicals&rft.au=Jordan,%20Ingo&rft.date=2011&rft.volume=39&rft.issue=1&rft.spage=50&rft.epage=58&rft.pages=50-58&rft.issn=1045-1056&rft.eissn=1095-8320&rft_id=info:doi/10.1016/j.biologicals.2010.11.005&rft_dat=%3Cproquest_cross%3E850559948%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c432t-cb9d292fa783c7296e8d7b27dd70909e3ce5b393317e66d41ca43c5a53d2a9833%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=850559948&rft_id=info:pmid/21237672&rfr_iscdi=true |